BR112023027104A2 - Compostos heterocíclicos como imunomoduladores de interações de pd-l1 - Google Patents
Compostos heterocíclicos como imunomoduladores de interações de pd-l1Info
- Publication number
- BR112023027104A2 BR112023027104A2 BR112023027104A BR112023027104A BR112023027104A2 BR 112023027104 A2 BR112023027104 A2 BR 112023027104A2 BR 112023027104 A BR112023027104 A BR 112023027104A BR 112023027104 A BR112023027104 A BR 112023027104A BR 112023027104 A2 BR112023027104 A2 BR 112023027104A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunomodulators
- interactions
- heterocyclic compounds
- disclosed
- inhibitory compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 title 1
- 108010074708 B7-H1 Antigen Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
compostos heterocíclicos como imunomoduladores de interações de pd-l1. são divulgados inibidores de pd-l1 de várias fórmulas de compostos, genérica e especificamente. são divulgados métodos de fabricação de tais compostos inibidores de pd-l1, genérica e especificamente. são divulgados métodos de uso de tais compostos inibidores de pd-l1 sozinho ou em combinação com agentes adicionais e composições de tais compostos inibidores de pd-l1 para o tratamento do câncer e outras condições.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/104258 WO2023272720A1 (en) | 2021-07-02 | 2021-07-02 | Heterocyclic compounds as immunomodulators of pd-l1 interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023027104A2 true BR112023027104A2 (pt) | 2024-03-12 |
Family
ID=77167907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023027104A BR112023027104A2 (pt) | 2021-07-02 | 2021-07-02 | Compostos heterocíclicos como imunomoduladores de interações de pd-l1 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4363408A1 (pt) |
| KR (1) | KR20240016318A (pt) |
| CN (1) | CN117616015A (pt) |
| AR (1) | AR126365A1 (pt) |
| AU (1) | AU2021454491A1 (pt) |
| BR (1) | BR112023027104A2 (pt) |
| CA (1) | CA3224665A1 (pt) |
| IL (1) | IL309620A (pt) |
| TW (1) | TW202313014A (pt) |
| WO (1) | WO2023272720A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
| WO2018119221A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| US10899735B2 (en) * | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
-
2021
- 2021-07-02 EP EP21749063.0A patent/EP4363408A1/en active Pending
- 2021-07-02 CA CA3224665A patent/CA3224665A1/en active Pending
- 2021-07-02 AU AU2021454491A patent/AU2021454491A1/en active Pending
- 2021-07-02 BR BR112023027104A patent/BR112023027104A2/pt unknown
- 2021-07-02 WO PCT/CN2021/104258 patent/WO2023272720A1/en active Application Filing
- 2021-07-02 CN CN202180099727.8A patent/CN117616015A/zh active Pending
- 2021-07-02 KR KR1020237044644A patent/KR20240016318A/ko active Search and Examination
- 2021-07-02 IL IL309620A patent/IL309620A/en unknown
-
2022
- 2022-07-01 TW TW111124676A patent/TW202313014A/zh unknown
- 2022-07-01 AR ARP220101738A patent/AR126365A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4363408A1 (en) | 2024-05-08 |
| CA3224665A1 (en) | 2023-01-05 |
| IL309620A (en) | 2024-02-01 |
| WO2023272720A1 (en) | 2023-01-05 |
| KR20240016318A (ko) | 2024-02-06 |
| AU2021454491A1 (en) | 2024-01-18 |
| TW202313014A (zh) | 2023-04-01 |
| AR126365A1 (es) | 2023-10-11 |
| CN117616015A (zh) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| CL2019002895A1 (es) | Inhibidores de pd-1/pd-l1. | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| BR112018073329A2 (pt) | combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| CR20220169A (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
| TR201911244T4 (tr) | İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı. | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| BR112017026682A2 (pt) | novos compostos bicíclicos como inibidores de dupla ação de atx/ca | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| MX2019010717A (es) | Derivados de indol como inhibidores de bomba de eflujo. | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| WO2020247701A3 (en) | Inhibitors of sarm1 | |
| BR112019026577A8 (pt) | Compostos aminotiazol como inibidores de proteína quinase | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| MX2019007797A (es) | Antagonistas de integrinas. | |
| MX2022002069A (es) | Inhibidores de enzimas. | |
| AU2016245434A8 (en) | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto | |
| BR112023027104A2 (pt) | Compostos heterocíclicos como imunomoduladores de interações de pd-l1 | |
| ATE527264T1 (de) | Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen | |
| BR112015023280A2 (pt) | derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase |